MTOR and diabetes mellitus: Liraglutide, a type of GLP-1 receptor agonist, was figured out could decrease diabetes-induced cell loss and pyknosis and improve cognitive function that acts by increasing mTOR expression via the AMPK and PI3K/Akt pathways [27].